pentoxifylline has been researched along with Dysmyelopoietic Syndromes in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tumor necrosis factor-alpha (TNF-alpha) levels were measured in the serum (sTNF-alpha) or bone marrow (BM) biopsies of 43 patients with myelodysplastic syndromes (MDS) who subsequently received therapy with a combination of pentoxifylline and ciprofloxacin (PC) with or without dexamethasone (PCD)." | 5.08 | Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. ( Dar, S; Qawi, H; Raza, A; Reza, S; Shetty, V, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erikci, AA | 1 |
| Ozturk, A | 1 |
| Karagoz, B | 1 |
| Bilgi, O | 1 |
| Turken, O | 1 |
| Top, C | 1 |
| Kandemir, EG | 1 |
| Kim, MK | 1 |
| Lee, JL | 1 |
| Cho, HS | 1 |
| Bae, SH | 1 |
| Ryoo, HM | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Nemunaitis, J | 1 |
| Rosenfeld, C | 1 |
| Getty, L | 1 |
| Boegel, F | 1 |
| Meyer, W | 1 |
| Jennings, LW | 1 |
| Zeigler, Z | 1 |
| Shadduck, R | 1 |
| Reza, S | 2 |
| Shetty, V | 2 |
| Dar, S | 2 |
| Qawi, H | 2 |
| Raza, A | 4 |
| Mundle, SD | 1 |
| Ali, A | 1 |
| Mativi, Y | 1 |
| Venugopal, P | 2 |
| Gregory, SA | 1 |
| Lisak, L | 1 |
| Andric, T | 1 |
| Andrews, C | 1 |
| Gezer, S | 1 |
| Gregory, S | 1 |
| Loew, J | 1 |
| Robin, E | 1 |
| Rifkin, S | 1 |
| Hsu, WT | 1 |
| Huang, RW | 1 |
| Novitzky, N | 1 |
| Mohamed, R | 1 |
| Finlayson, J | 1 |
| du Toit, C | 1 |
1 review available for pentoxifylline and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
Topics: Arthritis, Rheumatoid; Crohn Disease; Etanercept; Humans; Immunoglobulin G; Myelodysplastic Syndrome | 2000 |
3 trials available for pentoxifylline and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Apoptosis; Ciprofloxacin; | 2006 |
Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial.
Topics: Adult; Aged; Ciprofloxacin; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Hematopoi | 1995 |
Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Biopsy; Ciprofloxacin; Dexamethasone; Drug Therapy, Combination; Female; He | 1998 |
4 other studies available for pentoxifylline and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethason | 2008 |
Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes.
Topics: Apoptosis; Bone Marrow Cells; Caspase 1; Caspase 3; Caspases; Cell Separation; Cells, Cultured; HL-6 | 1999 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes.
Topics: Anti-Inflammatory Agents; Antigens, CD34; Apoptosis; Blood Transfusion; Bone Marrow Cells; Cell Divi | 2000 |